U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute PainPRNewsWire • 05/18/26
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking Alpha • 05/12/26
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater ChinaZacks Investment Research • 05/07/26
Exploring Analyst Estimates for Viatris (VTRS) Q1 Earnings, Beyond Revenue and EPSZacks Investment Research • 05/06/26
Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific MeetingPRNewsWire • 05/01/26
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingPRNewsWire • 04/10/26
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines TranscriptSeeking Alpha • 03/25/26
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)PRNewsWire • 03/23/26
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030PRNewsWire • 03/19/26
Viatris settles lawsuit over use of woman's 'immortal' cells to power drug researchReuters • 03/12/26